hesperidin

• Brachial artery flow-mediated dilation

  increases, p = 0.02, n = 24

  hesperidin treatment increased flow-mediated dilation (10.26 ± 1.19 vs. 7.78 ± 0.76%; P = 0.02)

  PMID:21346065 · one of two readings recorded this

• hesperetin stimulation of Src, Akt, AMP kinase and endothelial NO synthase phosphorylation in bovine aortic endothelial cells

  increases, acute stimulation of phosphorylation to produce NO, requiring H2O2

  Not recorded as a finding: Mechanism lane: the cell work dosed hesperetin, the metabolite, not hesperidin, so it was not filed under the hesperidin subject

  Treatment of BAEC with hesperetin acutely stimulated phosphorylation of Src, Akt, AMP kinase, and endothelial NO synthase to produce NO; this required generation of H(2)O(2).

  PMID:21346065 · one of two readings recorded this

• High-sensitivity C-reactive protein

  decreases, n = 24

  reduced concentrations of circulating inflammatory biomarkers (high-sensitivity C-reactive protein, serum amyloid A protein, soluble E-selectin)

  PMID:21346065 · one of two readings recorded this

• Monocyte adhesion to BAEC after TNF-α

  decreases

  Increased adhesion of monocytes to BAEC and expression of vascular cell adhesion molecule-1 in response to TNF-α treatment was reduced by pretreatment with hesperetin

  PMID:21346065 · one of two readings recorded this

• serum amyloid A protein and soluble E-selectin concentrations, assay not stated

  decreases, reduced versus placebo, no estimate in abstract

  Not recorded as a finding: no node for serum amyloid A or soluble E-selectin

  In the clinical study, when compared with placebo, hesperidin treatment increased flow-mediated dilation (10.26 ± 1.19 vs. 7.78 ± 0.76%; P = 0.02) and reduced concentrations of circulating inflammatory biomarkers (high-sensitivity C-reactive protein, serum amyloid A protein, soluble E-selectin).

  PMID:21346065 · one of two readings recorded this

• serum amyloid A protein, circulating concentration

  decreases, reduced with hesperidin versus placebo, no magnitude given

  Not recorded as a finding: no_outcome_node: no serum amyloid A outcome in the list

  In the clinical study, when compared with placebo, hesperidin treatment increased flow-mediated dilation (10.26 ± 1.19 vs. 7.78 ± 0.76%; P = 0.02) and reduced concentrations of circulating inflammatory biomarkers (high-sensitivity C-reactive protein, serum amyloid A protein, soluble E-selectin).

  PMID:21346065 · one of two readings recorded this

• Serum amyloid A protein

  decreases, n = 24

  reduced concentrations of circulating inflammatory biomarkers (high-sensitivity C-reactive protein, serum amyloid A protein, soluble E-selectin)

  PMID:21346065 · one of two readings recorded this

• soluble E-selectin, circulating concentration

  decreases, reduced with hesperidin versus placebo, no magnitude given

  Not recorded as a finding: no_outcome_node: no soluble E-selectin outcome in the list

  In the clinical study, when compared with placebo, hesperidin treatment increased flow-mediated dilation (10.26 ± 1.19 vs. 7.78 ± 0.76%; P = 0.02) and reduced concentrations of circulating inflammatory biomarkers (high-sensitivity C-reactive protein, serum amyloid A protein, soluble E-selectin).

  PMID:21346065 · one of two readings recorded this

• Soluble E-selectin

  decreases, n = 24

  reduced concentrations of circulating inflammatory biomarkers (high-sensitivity C-reactive protein, serum amyloid A protein, soluble E-selectin)

  PMID:21346065 · one of two readings recorded this

• VCAM-1 expression in BAEC after TNF-α

  decreases

  Increased adhesion of monocytes to BAEC and expression of vascular cell adhesion molecule-1 in response to TNF-α treatment was reduced by pretreatment with hesperetin

  PMID:21346065 · one of two readings recorded this

• Average fold change of down-regulated genes

  decreases, n = 10

  For the hesperidin group, 1,033 genes were upregulated, with an average fold change of 1.34, and 786 genes were down-regulated, with an average fold change of −1.25

  PMID:22110589 · one of two readings recorded this

• Average fold change of down-regulated genes

  decreases, n = 10

  Among the genes modulated by orange juice consumption, 1,706 were up-regulated and 1,716 genes were down-regulated, with an average fold change of 1.42 and −1.30, respectively

  PMID:22110589 · one of two readings recorded this

• Average fold change of up-regulated genes

  increases, n = 10

  For the hesperidin group, 1,033 genes were upregulated, with an average fold change of 1.34, and 786 genes were down-regulated, with an average fold change of −1.25

  PMID:22110589 · one of two readings recorded this

• Average fold change of up-regulated genes

  increases, n = 10

  Among the genes modulated by orange juice consumption, 1,706 were up-regulated and 1,716 genes were down-regulated, with an average fold change of 1.42 and −1.30, respectively

  PMID:22110589 · one of two readings recorded this

• leukocyte global gene expression profile by human whole-genome oligonucleotide cDNA microarray, number of differentially expressed genes (Bonferroni-corrected) after 4 weeks of hesperidin capsules versus placebo

  Not recorded as a finding: this platform holds no node for the endpoint

  Using this approach, we identified 3,422 genes as differentially expressed by orange juice (Table S2) and 1,819 genes by hesperidin (Table S3).

  PMID:22110589 · one of two readings recorded this

• leukocyte global gene expression profile, whole-genome oligonucleotide microarray, after 4 weeks of control drink plus hesperidin capsules versus control drink plus placebo

  unclear

  Not recorded as a finding: this platform holds no node for the endpoint

  Using this approach, we identified 3,422 genes as differentially expressed by orange juice (Table S2) and 1,819 genes by hesperidin (Table S3).

  PMID:22110589 · one of two readings recorded this

• Number of differentially expressed genes in blood leukocytes

  modulates, n = 10

  we identified 3,422 genes as differentially expressed by orange juice (Table S2) and 1,819 genes by hesperidin (Table S3)

  PMID:22110589 · one of two readings recorded this

• Number of differentially expressed genes in blood leukocytes

  modulates, n = 10

  we identified 3,422 genes as differentially expressed by orange juice (Table S2) and 1,819 genes by hesperidin (Table S3)

  PMID:22110589 · one of two readings recorded this

• Number of down-regulated genes

  decreases, n = 10

  For the hesperidin group, 1,033 genes were upregulated, with an average fold change of 1.34, and 786 genes were down-regulated, with an average fold change of −1.25

  PMID:22110589 · one of two readings recorded this

• Number of down-regulated genes

  decreases, n = 10

  Among the genes modulated by orange juice consumption, 1,706 were up-regulated and 1,716 genes were down-regulated, with an average fold change of 1.42 and −1.30, respectively

  PMID:22110589 · one of two readings recorded this

• Number of genes regulated in the same direction by both orange juice and hesperidin

  modulates, n = 10

  Interestingly, 1,582 of these genes overlapped with the same direction of change between the 2 groups

  PMID:22110589 · one of two readings recorded this

• Number of up-regulated genes

  increases, n = 10

  For the hesperidin group, 1,033 genes were upregulated, with an average fold change of 1.34, and 786 genes were down-regulated, with an average fold change of −1.25

  PMID:22110589 · one of two readings recorded this

• Number of up-regulated genes

  increases, n = 10

  Among the genes modulated by orange juice consumption, 1,706 were up-regulated and 1,716 genes were down-regulated, with an average fold change of 1.42 and −1.30, respectively

  PMID:22110589 · one of two readings recorded this

• abdominal fat area (total, subcutaneous, visceral) by umbilical CT with Fat Scan software, body weight, BMI and serum triglycerides over 12 weeks

  no effect, G-hesperidin alone did not differ from placebo on serum triglycerides; caffeine-containing arms decreased abdominal fat area

  Not recorded as a finding: subject_absent

  However, TG levels in the G-hesperidin-alone group did not decrease during the intervention period, and the changes from baseline (week 0) were not different from those of the placebo group.

  PMID:26786000 · one of two readings recorded this

• BMI change at week 12

  n = 15

  GH + Caf 25 | 15 | −0.05 ± 0.31 | −0.14 ± 0.40 | −0.23 ± 0.40 | −0.19 ± 0.65

  PMID:26786000 · one of two readings recorded this

• BMI change at week 12

  n = 15

  GH + Caf 50 | 15 | −0.13 ± 0.42 | −0.19 ± 0.52 | −0.28 ± 0.56 | −0.27 ± 0.70

  PMID:26786000 · one of two readings recorded this

• BMI change at week 12

  decreases, n = 15

  GH + Caf 75 | 15 | −0.13 ± 0.41 | −0.35 ± 0.55# | −0.56 ± 0.74# | −0.51 ± 0.84

  PMID:26786000 · one of two readings recorded this

• BMI change at week 12

  n = 15

  GH | 15 | −0.15 ± 0.36 | −0.01 ± 0.38 | −0.13 ± 0.42 | 0.03 ± 0.53

  PMID:26786000 · one of two readings recorded this

• BMI change at week 12

  n = 14

  ΔBMI (kg/m2) | Placebo | 14 | −0.07 ± 0.37 | 0.14 ± 0.39 | −0.02 ± 0.58 | 0.08 ± 0.57

  PMID:26786000 · one of two readings recorded this

• BMI decrease versus placebo, week 8 and week 12

  decreases

  Decreases in the BMI in the G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group at week 8 and week 12

  PMID:26786000 · one of two readings recorded this

• Body weight change at week 12

  n = 15

  GH + Caf 25 | 15 | −0.11 ± 0.8 | −0.39 ± 1.0 | −0.57 ± 1.1 | −0.48 ± 1.7

  PMID:26786000 · one of two readings recorded this

• Body weight change at week 12

  n = 15

  GH + Caf 50 | 15 | −0.29 ± 1.1 | −0.44 ± 1.3 | −0.67 ± 1.4 | −0.67 ± 1.8

  PMID:26786000 · one of two readings recorded this

• Body weight change at week 12

  n = 15

  GH + Caf 75 | 15 | −0.36 ± 1.0 | −0.88 ± 1.4# | −1.43 ± 2.0 | −1.27 ± 2.2

  PMID:26786000 · one of two readings recorded this

• Body weight change at week 12

  n = 15

  GH | 15 | −0.44 ± 1.0 | −0.09 ± 0.9 | −0.39 ± 1.1 | 0.08 ± 1.4

  PMID:26786000 · one of two readings recorded this

• Body weight change at week 12

  n = 14

  ΔBody weight (kg) | Placebo | 14 | −0.26 ± 1.1 | 0.24 ± 1.2 | −0.19 ± 1.7 | 0.16 ± 1.7

  PMID:26786000 · one of two readings recorded this

• Body weight decrease versus placebo, week 12

  no effect, p = 0.089

  Decreases in body weight at week 8 (p = 0.045) but not at week 12 (p = 0.089) were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group

  PMID:26786000 · one of two readings recorded this

• Body weight decrease versus placebo, week 8

  decreases, p = 0.045

  Decreases in body weight at week 8 (p = 0.045) but not at week 12 (p = 0.089) were significantly greater in the G-hesperidin with 75-mg caffeine group than in the placebo group

  PMID:26786000 · one of two readings recorded this

• Decrease in subcutaneous fat area versus placebo

  decreases

  Decreases in SFA in the G-hesperidin with 50-mg caffeine group and G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group

  PMID:26786000 · one of two readings recorded this

• Decrease in total fat area versus placebo

  decreases

  Decreases in TFA in the G-hesperidin with 50-mg caffeine group and in the G-hesperidin with 75-mg caffeine group were significantly greater than those in the placebo group

  PMID:26786000 · one of two readings recorded this

• Decrease in visceral fat area versus placebo

  no effect

  there were no significant decreases in VFA between the placebo group and groups that ingested G-hesperidin with or without caffeine

  PMID:26786000 · one of two readings recorded this

• Energy intake and exercise volume

  no effect

  Occasionally, significant differences were found within groups, but there was no significant difference between groups

  PMID:26786000 · one of two readings recorded this

• HDL-cholesterol change at week 12

  n = 15

  GH + Caf 25 | 15 | −0.5 ± 4.9 | −4.6 ± 4.4 | −4.0 ± 3.9 | −3.1 ± 4.4

  PMID:26786000 · one of two readings recorded this

• HDL-cholesterol change at week 12

  n = 15

  GH + Caf 50 | 15 | −2.1 ± 5.1 | −3.9 ± 7.1 | −3.5 ± 4.8 | −1.9 ± 8.2

  PMID:26786000 · one of two readings recorded this

• HDL-cholesterol change at week 12

  n = 15

  GH + Caf 75 | 15 | −0.3 ± 6.7 | −1.5 ± 6.4 | −2.2 ± 5.7 | −1.4 ± 5.8

  PMID:26786000 · one of two readings recorded this

• HDL-cholesterol change at week 12

  n = 15

  GH | 15 | −2.1 ± 5.4 | −1.6 ± 4.4 | −3.0 ± 5.6 | −2.1 ± 4.8

  PMID:26786000 · one of two readings recorded this

• HDL-cholesterol change at week 12

  n = 14

  ΔHDL-cholesterol (mg/dl) | Placebo | 14 | −2.8 ± 6.2 | −3.1 ± 4.7 | −2.8 ± 5.0 | −1.6 ± 5.6

  PMID:26786000 · one of two readings recorded this

• Hip circumference change at week 12

  n = 15

  GH + Caf 25 | 15 | 0.23 ± 0.8 | 0.17 ± 1.0 | 0.13 ± 1.4 | 0.06 ± 2.0

  PMID:26786000 · one of two readings recorded this

• Hip circumference change at week 12

  n = 15

  GH + Caf 50 | 15 | −0.26 ± 0.8 | −0.11 ± 1.3 | −0.08 ± 1.7 | −0.13 ± 2.0

  PMID:26786000 · one of two readings recorded this

• Hip circumference change at week 12

  n = 15

  GH + Caf 75 | 15 | −0.21 ± 1.0 | −0.39 ± 1.2 | −0.85 ± 1.8 | −0.79 ± 2.0

  PMID:26786000 · one of two readings recorded this

• Hip circumference change at week 12

  n = 15

  GH | 15 | −0.17 ± 0.8 | 0.05 ± 1.3 | −0.41 ± 1.2 | −0.23 ± 1.5

  PMID:26786000 · one of two readings recorded this

• Hip circumference change at week 12

  n = 14

  ΔHip (cm) | Placebo | 14 | −0.17 ± 0.7 | 0.01 ± 1.1 | 0.37 ± 1.6 | 0.64 ± 1.4

  PMID:26786000 · one of two readings recorded this

• Hip circumference decrease versus placebo

  no effect

  There were no significant differences in decreases in hip circumference between the placebo group, and groups that ingested G-hesperidin with or without caffeine

  PMID:26786000 · one of two readings recorded this

• LDL-cholesterol change at week 12

  n = 15

  GH + Caf 25 | 15 | −2.6 ± 21 | −5.9 ± 18 | −7.5 ± 14 | −5.9 ± 15

  PMID:26786000 · one of two readings recorded this

• LDL-cholesterol change at week 12

  n = 15

  GH + Caf 50 | 15 | −2.7 ± 16 | −2.3 ± 18 | −1.0 ± 14 | −2.8 ± 15

  PMID:26786000 · one of two readings recorded this

• LDL-cholesterol change at week 12

  n = 15

  GH + Caf 75 | 15 | 1.1 ± 31 | −8.9 ± 20 | −12.2 ± 21 | −1.5 ± 23

  PMID:26786000 · one of two readings recorded this

• LDL-cholesterol change at week 12

  n = 15

  GH | 15 | −11.0 ± 17 | −3.1 ± 15 | −10.6 ± 14 | −7.5 ± 14

  PMID:26786000 · one of two readings recorded this

• LDL-cholesterol change at week 12

  n = 14

  ΔLDL-cholesterol (mg/dL) | Placebo | 14 | −5.6 ± 17 | −2.4 ± 15 | −2.8 ± 16 | 0.9 ± 21

  PMID:26786000 · one of two readings recorded this

• Serum triglyceride change at week 12

  n = 15

  GH + Caf 25 | 15 | 11.1 ± 49 | 8.9 ± 51 | 3.0 ± 44 | 1.0 ± 46

  PMID:26786000 · one of two readings recorded this

• Serum triglyceride change at week 12

  n = 15

  GH + Caf 50 | 15 | 4.4 ± 69 | 2.9 ± 70 | 15.3 ± 45 | 10.7 ± 54

  PMID:26786000 · one of two readings recorded this

• Serum triglyceride change at week 12

  n = 15

  GH + Caf 75 | 15 | −21.9 ± 80 | −29.3 ± 66 | −22.7 ± 61 | −21.3 ± 74

  PMID:26786000 · one of two readings recorded this

• Serum triglyceride change at week 12

  no effect, n = 15

  GH | 15 | 4.3 ± 33 | 5.5 ± 46 | 24.6 ± 60 | 24.0 ± 47

  PMID:26786000 · one of two readings recorded this

• Serum triglyceride change at week 12

  n = 14

  ΔTriglyceride (mg/dl) | Placebo | 14 | −1.4 ± 58 | −12.4 ± 49 | −2.6 ± 57 | −24.9 ± 50

  PMID:26786000 · one of two readings recorded this

• Serum triglyceride change from baseline versus placebo

  no effect

  TG levels in the G-hesperidin-alone group did not decrease during the intervention period, and the changes from baseline (week 0) were not different from those of the placebo group

  PMID:26786000 · one of two readings recorded this

• Subcutaneous fat area, change from baseline at week 12

  n = 15

  GH + Caf 25 | 15 | 190.4 ± 59.0 | 190.1 ± 60.1 | −0.4 ± 14.3

  PMID:26786000 · one of two readings recorded this

• Subcutaneous fat area, change from baseline at week 12

  decreases, n = 15

  GH + Caf 50 | 15 | 187.0 ± 48.0 | 177.7 ± 44.0 | −9.3 ± 17.1##

  PMID:26786000 · one of two readings recorded this

• Subcutaneous fat area, change from baseline at week 12

  decreases, n = 15

  GH + Caf 75 | 15 | 209.8 ± 45.4 | 197.3 ± 44.4* | −12.4 ± 18.7##

  PMID:26786000 · one of two readings recorded this

• Subcutaneous fat area, change from baseline at week 12

  n = 15

  GH | 15 | 206.6 ± 45.4 | 203.1 ± 44.2 | −3.5 ± 11.8

  PMID:26786000 · one of two readings recorded this

• Subcutaneous fat area, change from baseline at week 12

  n = 14

  Subcutaneous fat area (cm2) | Placebo | 14 | 204.6 ± 59.5 | 215.8 ± 63.5* | 11.2 ± 18.3

  PMID:26786000 · one of two readings recorded this

• Total cholesterol change at week 12

  n = 15

  GH + Caf 25 | 15 | −3.3 ± 17 | −11.3 ± 21 | −8.2 ± 16 | −8.5 ± 17

  PMID:26786000 · one of two readings recorded this

• Total cholesterol change at week 12

  n = 15

  GH + Caf 50 | 15 | −4.5 ± 16 | −6.1 ± 18 | 0 ± 15 | −3.2 ± 22

  PMID:26786000 · one of two readings recorded this

• Total cholesterol change at week 12

  n = 15

  GH + Caf 75 | 15 | −5.3 ± 22 | −15.5 ± 21 | −13.1 ± 14 | −7.6 ± 22

  PMID:26786000 · one of two readings recorded this

• Total cholesterol change at week 12

  n = 15

  GH | 15 | −12.5 ± 17 | −5.3 ± 15 | −5.8 ± 14 | −7.6 ± 16

  PMID:26786000 · one of two readings recorded this

• Total cholesterol change at week 12

  n = 14

  ΔTotal cholesterol (mg/dl) | Placebo | 14 | −4.8 ± 20 | −5.2 ± 16 | −0.1 ± 18 | −1.9 ± 24

  PMID:26786000 · one of two readings recorded this

• Total cholesterol, HDL-C and LDL-C change from baseline versus placebo

  no effect

  but changes from baseline (week 0) were not different from those in the placebo group

  PMID:26786000 · one of two readings recorded this

• Total fat area, change from baseline at week 12

  n = 15

  GH + Caf 25 | 15 | 297.9 ± 54.8 | 293.7 ± 61.5 | −4.2 ± 18.2

  PMID:26786000 · one of two readings recorded this

• Total fat area, change from baseline at week 12

  decreases, n = 15

  GH + Caf 50 | 15 | 295.1 ± 53.7 | 286.7 ± 48.9 | −8.4 ± 21.9#

  PMID:26786000 · one of two readings recorded this

• Total fat area, change from baseline at week 12

  decreases, n = 15

  GH + Caf 75 | 15 | 310.8 ± 43.9 | 293.9 ± 45.5 | −17.0 ± 31.4##

  PMID:26786000 · one of two readings recorded this

• Total fat area, change from baseline at week 12

  n = 15

  GH | 15 | 304.3 ± 41.8 | 299.7 ± 44.1 | −4.6 ± 20.5

  PMID:26786000 · one of two readings recorded this

• Total fat area, change from baseline at week 12

  n = 14

  Total fat area (cm2) | Placebo | 14 | 301.7 ± 50.6 | 318.1 ± 50.4 | 16.3 ± 34.1

  PMID:26786000 · one of two readings recorded this

• Visceral fat area, change from baseline at week 12

  n = 15

  GH + Caf 25 | 15 | 107.5 ± 42.3 | 103.6 ± 40.0 | −3.8 ± 14.5

  PMID:26786000 · one of two readings recorded this

• Visceral fat area, change from baseline at week 12

  n = 15

  GH + Caf 50 | 15 | 108.1 ± 46.1 | 109.0 ± 46.6 | 0.9 ± 11.3

  PMID:26786000 · one of two readings recorded this

• Visceral fat area, change from baseline at week 12

  n = 15

  GH + Caf 75 | 15 | 101.1 ± 28.9 | 96.5 ± 33.7 | −4.5 ± 16.1

  PMID:26786000 · one of two readings recorded this

• Visceral fat area, change from baseline at week 12

  n = 15

  GH | 15 | 97.6 ± 27.7 | 96.6 ± 27.5 | −1.1 ± 15.0

  PMID:26786000 · one of two readings recorded this

• Visceral fat area, change from baseline at week 12

  n = 14

  Visceral fat area (cm2) | Placebo | 14 | 97.2 ± 53.1 | 102.3 ± 61.9 | 5.1 ± 25.9

  PMID:26786000 · one of two readings recorded this

• Waist circumference change at week 12

  decreases, n = 15

  GH + Caf 25 | 15 | −0.49 ± 1.1 | −1.17 ± 1.4# | −1.31 ± 1.6# | −0.96 ± 2.2

  PMID:26786000 · one of two readings recorded this

• Waist circumference change at week 12

  n = 15

  GH + Caf 50 | 15 | −0.31 ± 1.1 | −0.28 ± 1.3 | −0.82 ± 1.9 | −1.12 ± 2.6

  PMID:26786000 · one of two readings recorded this

• Waist circumference change at week 12

  n = 15

  GH + Caf 75 | 15 | 0.05 ± 1.0 | −0.66 ± 0.9 | −1.11 ± 1.7 | −1.21 ± 2.2

  PMID:26786000 · one of two readings recorded this

• Waist circumference change at week 12

  n = 15

  GH | 15 | 0.01 ± 1.0 | −0.01 ± 1.4 | −0.02 ± 1.3 | −0.03 ± 1.3

  PMID:26786000 · one of two readings recorded this

• Waist circumference change at week 12

  n = 14

  ΔWaist (cm) | Placebo | 14 | −0.12 ± 0.9 | 0.19 ± 1.4 | 0.44 ± 2 | 0.42 ± 2.1

  PMID:26786000 · one of two readings recorded this

• Waist circumference decrease versus placebo, week 8 and week 12

  decreases

  Decreases in waist circumference were significantly greater in the G-hesperidin with 25 mg caffeine group than in the placebo group at week-8 and at week-12

  PMID:26786000 · one of two readings recorded this

• Waist circumference decrease versus placebo

  no effect

  Similar decreases were observed in the G-hesperidin with 75 mg caffeine group but were not significant

  PMID:26786000 · one of two readings recorded this

• Catalase activity

  no effect

  However, these differences between groups were not statistically significant (Table 4)

  PMID:31416212 · one of two readings recorded this

• Superoxide dismutase activity

  no effect

  However, these differences were not statistically significant (Table 4)

  PMID:31416212 · one of two readings recorded this

• Average power, best sprint of repeated sprint test

  increases

  significant positive changes were observed in Cardiose® compared to placebo in average power, maximum speed, and total energy (∑ 4 sprint test)

  PMID:31416212 · one of two readings recorded this

• catalase activity, SOD activity, TBARS, GSH and GSSG/GSH ratio around the repeated sprint test

  no effect, differences between Cardiose and placebo not statistically significant

  Not recorded as a finding: every null sentence is agentless or names the analyte only as 'this antioxidant peptide', so no self-supporting quote exists

  However, these differences between groups were not statistically significant (Table 4).

  PMID:31416212 · one of two readings recorded this

• catalase activity, spectrophotometric H2O2 decomposition at 240 nm, between Cardiose and placebo

  no effect, differences between groups not statistically significant

  Not recorded as a finding: Sentence reports differences between groups without naming the compound in the sentence; agentless statement of a null

  However, these differences between groups were not statistically significant (Table 4).

  PMID:31416212 · one of two readings recorded this

• Correlation of urinary hesperidin metabolites with difference in total energy (sum of 4 sprints)

  increases, p = 0.043

  there was a positive significant correlation (r = 0.547; p = 0.043) between the levels of excreted hesperidin metabolites in urine and the difference in total energy (∑ 4 sprint test)

  PMID:31416212 · one of two readings recorded this

• Correlation of urinary hesperidin metabolites with percentage variation in catalase activity (E1 and E3)

  decreases, p = 0.013

  An inverse significant correlation between the levels of hesperidin metabolites excreted in urine and the percentage variations in the catalase activity at points E1 and E3 (r = −0.625; p = 0.013)

  PMID:31416212 · one of two readings recorded this

• Correlation of urinary hesperidin metabolites with percentage variation in GSH (01-02)

  increases, p = 0.033

  A positive significant correlation between the levels of hesperidin metabolites in urine and the percentage variations in the levels GSH %Δ 01-02 (r = 0.551; p = 0.033)

  PMID:31416212 · one of two readings recorded this

• Fat energy contribution, first to second rectangular test

  unclear

  Cardiose® led to a higher increase (+15.1%) in the fat energy contribution

  PMID:31416212 · one of two readings recorded this

• GSSG/GSH ratio

  no effect

  Despite this different behavior in the GSSG/GSH ratio during the test, differences in the GSSG/GSH ratio were not statistically significant (Table 4)

  PMID:31416212 · one of two readings recorded this

• maximum speed and total energy (sum of 4 sprints, J) in the repeated sprint test

  increases

  Not recorded as a finding: no node for sprint maximum speed or total sprint energy

  On one hand, taking into account the data corresponding to the best sprint, significant positive changes were observed in Cardiose® compared to placebo in average power, maximum speed, and total energy (∑ 4 sprint test).

  PMID:31416212 · one of two readings recorded this

• Maximum speed, best sprint of repeated sprint test

  increases

  significant positive changes were observed in Cardiose® compared to placebo in average power, maximum speed, and total energy (∑ 4 sprint test)

  PMID:31416212 · one of two readings recorded this

• Metabolic parameters during VT1 rectangular tests, pre-post change

  no effect

  During the VT1 testing period, no significant differences were observed in pre-post changes between Cardiose® and placebo group (Table 3)

  PMID:31416212 · one of two readings recorded this

• Peak power and time-to-peak power, best sprint of repeated sprint test

  no effect

  no significant changes were found in peak power and time-to-peak power comparing Cardiose® versus placebo group using these data

  PMID:31416212 · one of two readings recorded this

• peak power in the repeated 4 x 30 s Wingate sprint test, best-sprint data

  no effect, no significant changes in peak power and time-to-peak power, Cardiose versus placebo

  Not recorded as a finding: the quoted sentence depends on the preceding sentence for the best-sprint restriction ('using these data'), so it does not support the claim on its own

  However, no significant changes were found in peak power and time-to-peak power comparing Cardiose® versus placebo group using these data (Table 2).

  PMID:31416212 · one of two readings recorded this

• Peak power, time-to-peak and total energy, average of four sprints

  unclear

  positive changes were observed in the peak power, time-to-peak, and total energy in the Cardiose® group compared to placebo, but not reaching the statistically significance (Table 2)

  PMID:31416212 · one of two readings recorded this

• Reduced glutathione (GSH)

  no effect

  Despite levels of this antioxidant peptide being higher after Cardiose® supplementation at baseline and after the repeated sprint test, differences between treatments were not significant

  PMID:31416212 · one of two readings recorded this

• Respiratory exchange ratio, first to second rectangular test

  no effect

  respiratory exchange ratio (RER), which is the ratio between the amount of CO2 produced and oxygen used in metabolism, significantly decreased from the first to the second rectangular test in both groups, but without significant differences between them

  PMID:31416212 · one of two readings recorded this

• TBARS lipid peroxidation, phosphotungstic acid precipitation and thiobarbituric acid adduct read at 532 nm

  no effect, no significant changes between interventions or blood extraction points

  Not recorded as a finding: Agentless null sentence that never names the compound; node malondialdehyde-circulating requires the assay named and the sentence does not support the arm

  However, no significant changes were observed between interventions and between blood extraction points (Table 4).

  PMID:31416212 · one of two readings recorded this

• TBARS (lipid peroxidation)

  no effect

  However, no significant changes were observed between interventions and between blood extraction points (Table 4)

  PMID:31416212 · one of two readings recorded this

• Total energy (sum of 4 sprints), best sprint of repeated sprint test

  increases

  significant positive changes were observed in Cardiose® compared to placebo in average power, maximum speed, and total energy (∑ 4 sprint test)

  PMID:31416212 · one of two readings recorded this

• blood glucose control, subgroup analyses by study design, duration and health status

  no effect

  Subgroup analyses also indicated that the effects were not different based on the studies' design and duration, or the health status of the participants

  PMID:31489695 · one of two readings recorded this

• glycated haemoglobin A1c

  no effect

  glycated haemoglobin A1c (WMD = -0.04%, 95% CI: -0.14, 0.04)

  PMID:31489695 · one of two readings recorded this

• homeostasis model assessment for insulin resistance

  no effect

  homeostasis model assessment for insulin resistance (WMD = 0.117, 95% CI: -0.06, 0.29)

  PMID:31489695 · one of two readings recorded this

• plasma insulin concentration, pooled WMD in uU/mL

  no effect, WMD = -0.01 μU/mL, 95% CI: -1.20, 1.19

  Not recorded as a finding: no_outcome_node: no plasma insulin outcome in the list (only stimulated postprandial insulin)

  The results showed that hesperidin had no significant effect on serum fasting blood glucose (weighted mean difference [WMD] = -1.10 mg/dL, 95% CI: -3.79, 1.57), plasma insulin (WMD = -0.01 μU/mL, 95% CI: -1.20, 1.19), glycated haemoglobin A1c (WMD = -0.04%, 95% CI: -0.14, 0.04), homeostasis model assessment for insulin resistance (WMD = 0.117, 95% CI: -0.06, 0.29) and quantitative insulin sensitivity check index (WMD = 0.135; 95% CI: -0.13, 0.39), with no significant between-study heterogeneity.

  PMID:31489695 · one of two readings recorded this

• plasma insulin, immunoassay not stated

  no effect, WMD = -0.01 μU/mL, 95% CI: -1.20, 1.19

  Not recorded as a finding: no plasma insulin node in the outcome list

  The results showed that hesperidin had no significant effect on serum fasting blood glucose (weighted mean difference [WMD] = -1.10 mg/dL, 95% CI: -3.79, 1.57), plasma insulin (WMD = -0.01 μU/mL, 95% CI: -1.20, 1.19), glycated haemoglobin A1c (WMD = -0.04%, 95% CI: -0.14, 0.04), homeostasis model assessment for insulin resistance (WMD = 0.117, 95% CI: -0.06, 0.29) and quantitative insulin sensitivity check index (WMD = 0.135; 95% CI: -0.13, 0.39), with no significant between-study heterogeneity.

  PMID:31489695 · one of two readings recorded this

• plasma insulin

  no effect

  plasma insulin (WMD = -0.01 μU/mL, 95% CI: -1.20, 1.19)

  PMID:31489695 · one of two readings recorded this

• quantitative insulin sensitivity check index (QUICKI), pooled WMD

  no effect, WMD = 0.135; 95% CI: -0.13, 0.39

  Not recorded as a finding: no_outcome_node: no QUICKI outcome in the list

  The results showed that hesperidin had no significant effect on serum fasting blood glucose (weighted mean difference [WMD] = -1.10 mg/dL, 95% CI: -3.79, 1.57), plasma insulin (WMD = -0.01 μU/mL, 95% CI: -1.20, 1.19), glycated haemoglobin A1c (WMD = -0.04%, 95% CI: -0.14, 0.04), homeostasis model assessment for insulin resistance (WMD = 0.117, 95% CI: -0.06, 0.29) and quantitative insulin sensitivity check index (WMD = 0.135; 95% CI: -0.13, 0.39), with no significant between-study heterogeneity.

  PMID:31489695 · one of two readings recorded this

• quantitative insulin sensitivity check index (QUICKI)

  no effect, WMD = 0.135; 95% CI: -0.13, 0.39

  Not recorded as a finding: no QUICKI node in the outcome list

  The results showed that hesperidin had no significant effect on serum fasting blood glucose (weighted mean difference [WMD] = -1.10 mg/dL, 95% CI: -3.79, 1.57), plasma insulin (WMD = -0.01 μU/mL, 95% CI: -1.20, 1.19), glycated haemoglobin A1c (WMD = -0.04%, 95% CI: -0.14, 0.04), homeostasis model assessment for insulin resistance (WMD = 0.117, 95% CI: -0.06, 0.29) and quantitative insulin sensitivity check index (WMD = 0.135; 95% CI: -0.13, 0.39), with no significant between-study heterogeneity.

  PMID:31489695 · one of two readings recorded this

• quantitative insulin sensitivity check index

  no effect

  quantitative insulin sensitivity check index (WMD = 0.135; 95% CI: -0.13, 0.39)

  PMID:31489695 · one of two readings recorded this

• serum fasting blood glucose

  no effect

  serum fasting blood glucose (weighted mean difference [WMD] = -1.10 mg/dL, 95% CI: -3.79, 1.57)

  PMID:31489695 · one of two readings recorded this

• Serum uric acid

  decreases, p = 0.044

  Uric acid decreased at 12 weeks after EOJ treatment, reaching significance versus changes in the CD treatment (P = 0.044)

  PMID:32661681 · one of two readings recorded this

• Correlation of decrease in F2-isoprostanes with decrease in SBP

  increases, p = 0.042

  the decrease in F2-isoprostanes, although without significance, were directly correlated with the decreases in SBP (R = 0.178, P = 0.042)

  PMID:32661681 · one of two readings recorded this

• Correlation of decrease in PP with decrease in NAMPT expression

  increases, p = 0.037

  The decrease in PP at week 12 was directly related to that of NAMPT expression (R = 0.344, P = 0.037)

  PMID:32661681 · one of two readings recorded this

• Correlation of decrease in PP with decrease in PTX3 expression

  increases, p = 0.002

  The decreases in SBP and PP at week 12 were directly related to the decrease in PTX3 expression (R = 0.393, P = 0.016 and R = 0.487, P = 0.002, respectively)

  PMID:32661681 · one of two readings recorded this

• Correlation of decrease in SBP with decrease in PTX3 expression

  increases, p = 0.016

  The decreases in SBP and PP at week 12 were directly related to the decrease in PTX3 expression (R = 0.393, P = 0.016 and R = 0.487, P = 0.002, respectively)

  PMID:32661681 · one of two readings recorded this

• Correlation of increase in hesperidin-7-β-d-glucuronide with systolic blood pressure, postprandial

  decreases, p = 0.024

  At 6 h, an inverse relationship was also observed between the increase in hesperidin-7-β-d-glucuronide and SBP values (R = −0.353, P = 0.024)

  PMID:32661681 · one of two readings recorded this

• Correlation of NLRP3 expression change with PP change

  decreases, p = 0.01

  changes in NRLP3 expression were inversely related to those of PP at week 12 (R = −0.420, P = 0.010)

  PMID:32661681 · one of two readings recorded this

• Correlation of plasma hesperidin-7-β-d-glucuronide with pulse pressure, postprandial

  decreases, p = 0.023

  an inverse relationship was observed between hesperidin-7-β-d-glucuronide values and those of PP (R = −0.354, P = 0.023, and R = −0.377, P = 0.015, respectively)

  PMID:32661681 · one of two readings recorded this

• Correlation of plasma hesperidin-7-β-d-glucuronide with pulse pressure, postprandial

  decreases, p = 0.015

  an inverse relationship was observed between hesperidin-7-β-d-glucuronide values and those of PP (R = −0.354, P = 0.023, and R = −0.377, P = 0.015, respectively)

  PMID:32661681 · one of two readings recorded this

• Correlation of PTX3 expression with NAMPT expression

  increases, p = 0.001

  expression of PTX3 at week 12 was directly related to that of NAMPT (R = 0.759, P < 0.001)

  PMID:32661681 · one of two readings recorded this

• Correlation of SBP with ICAM-1

  increases, p = 0.004

  After 12 weeks sustained consumption, the values of SBP directly correlated with those of ICAM-1 (R = 0.251, P = 0.004) and VCAM (R = 0.185, P = 0.036)

  PMID:32661681 · one of two readings recorded this

• Correlation of SBP with VCAM-1

  increases, p = 0.036

  After 12 weeks sustained consumption, the values of SBP directly correlated with those of ICAM-1 (R = 0.251, P = 0.004) and VCAM (R = 0.185, P = 0.036)

  PMID:32661681 · one of two readings recorded this

• Correlation of uric acid with SBP, DBP and PP

  increases, p = 0.05

  At week 12 after sustained consumption, uric acid concentrations were directly related to SBP, DBP, and PP (P < 0.05)

  PMID:32661681 · one of two readings recorded this

• Diastolic blood pressure after a single 500 mL dose, after 12 weeks of treatment

  decreases, p = 0.05

  DBP decreased versus baseline at all evaluated times (P < 0.05), and the decrease at 2 h and 6 h reached significance versus changes in CD (P < 0.05)

  PMID:32661681 · one of two readings recorded this

• Diastolic blood pressure after a single 500 mL dose, start of study

  no effect

  No changes were observed in DBP values

  PMID:32661681 · one of two readings recorded this

• Diastolic blood pressure change

  decreases, p = 0.05

  DBP decreased similarly after all interventions and in all weeks (P < 0.05)

  PMID:32661681 · one of two readings recorded this

• office systolic and diastolic blood pressure and pulse pressure (OMRON HEM-907 automatic sphygmomanometer, seated, mean of two readings), sustained 12 weeks and single-dose postprandial

  decreases, SBP decreased in a dose-dependent manner with the beverage hesperidin content (linear trend across control, OJ and EOJ)

  Not recorded as a finding: the intervention held more than the compound

  SBP decreased in a dose-dependent manner with the hesperidin content of the beverage administered (P < 0.05 for linear trend).

  PMID:32661681 · one of two readings recorded this

• PBMC expression of PTX3 and NAMPT

  decreases, p = 0.05

  The expressions of the PTX3 and NAMPT genes decreased significantly in PBMC after the EOJ intervention versus the control treatment (P < 0.05)

  PMID:32661681 · one of two readings recorded this

• Plasma hesperetin-7-β-d-glucuronide, differential metabolite versus control

  increases, p = 0.001

  At 12 weeks, the metabolite hesperetin-7-β-d-glucuronide was the main differentially expressed metabolite between the OJ and EOJ groups and the CD group (P < 0.001)

  PMID:32661681 · one of two readings recorded this

• Plasma hesperetin-7-β-d-glucuronide, single-dose studies

  increases, p = 0.005

  plasma hesperetin-7-β-d-glucuronide increased at 4 and 6 h after OJ and EOJ (P < 0.005 versus changes in CD)

  PMID:32661681 · one of two readings recorded this

• Plasma hesperetin-7-β-d-glucuronide, trend with hesperidin content

  increases, p = 0.001

  After 12 weeks of treatments, plasma hesperetin-7-β-d-glucuronide increased in a dose-dependent manner with the hesperidin content of the beverage administered (P < 0.001 for linear trend)

  PMID:32661681 · one of two readings recorded this

• Plasma hesperetin-7-β-d-glucuronide

  increases, p = 0.05

  and the increase in the EOJ group was significantly higher than that of the OJ group (P < 0.05)

  PMID:32661681 · one of two readings recorded this

• Plasma homocysteine, postprandial after 12 weeks

  decreases, p = 0.05

  homocysteine plasma values decreased in the postprandial state at 2 h and 4 h after OJ and after 2 h of EOJ ingestion (P < 0.05)

  PMID:32661681 · one of two readings recorded this

• Plasma homocysteine, sustained consumption

  decreases

  At week 12 after sustained consumption, homocysteine values decreased after OJ and EOJ treatments, and the decreases reached significance versus changes after the CD treatment

  PMID:32661681 · one of two readings recorded this

• Protein intake (% energy)

  unclear, p = 0.031

  No differences in dietary intake were observed among groups with exception of protein (% energy) intake, which was greater in the OJ group than in the EOJ one (P = 0.031)

  PMID:32661681 · one of two readings recorded this

• Pulse pressure after a single 500 mL dose, after 12 weeks of treatment

  decreases, p = 0.05

  the observed decreases in SBP at 6 h and those of PP at all evaluated times reached significance versus changes in CD (P < 0.05)

  PMID:32661681 · one of two readings recorded this

• Pulse pressure after a single 500 mL dose, start of study

  decreases, p = 0.05

  significant decreases were observed in SBP at 2 h and in PP at all evaluated times (P < 0.05) after a single dose of 500 mL only in the case of EOJ

  PMID:32661681 · one of two readings recorded this

• Pulse pressure, trend with hesperidin content

  decreases, p = 0.05

  PP decreased in a dose-dependent manner with the hesperidin content of the beverage administered (P < 0.05 for linear trend) in all weeks

  PMID:32661681 · one of two readings recorded this

• Pulse pressure, trend with hesperidin content

  no effect, p = 0.125

  but in the 12 week, the trend did not reach significance (P = 0.125)

  PMID:32661681 · one of two readings recorded this

• Serum ICAM-1

  decreases, p = 0.032

  ICAM-1 decreased at week 12 after EOJ treatment (P = 0.032), but no changes were observed between treatments

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure after a single 500 mL dose, after 12 weeks of treatment

  decreases, p = 0.05

  the observed decreases in SBP at 6 h and those of PP at all evaluated times reached significance versus changes in CD (P < 0.05)

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure after a single 500 mL dose, start of study

  decreases, p = 0.05

  significant decreases were observed in SBP at 2 h and in PP at all evaluated times (P < 0.05) after a single dose of 500 mL only in the case of EOJ

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure, average change of all weeks

  decreases

  The average of all decreases through the study was −6.35 and −7.36 mmHg for OJ and EOJ interventions, respectively

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure, average change of all weeks

  decreases

  The average of all decreases through the study was −6.35 and −7.36 mmHg for OJ and EOJ interventions, respectively

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure change

  decreases, p = 0.05

  After consumption of EOJ, SBP decreased in all evaluated weeks compared to CD, the decreases reaching significance (P < 0.05) at all weeks

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure change

  unclear, p = 0.078

  with the only exception of week 8 in which a borderline significance (P = 0.078) was observed

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure change

  decreases, p = 0.05

  in the CD at week 4 and 12 (P < 0.05) by mean 95% IC −5.58 (−9.8; −1.3) mmHg and −5.06 (−8.8; −1.3) mmHg, respectively

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure change

  decreases, p = 0.05

  in the CD at week 4 and 12 (P < 0.05) by mean 95% IC −5.58 (−9.8; −1.3) mmHg and −5.06 (−8.8; −1.3) mmHg, respectively

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure change

  unclear, p = 0.056

  A borderline significance at week 8 was also observed (P = 0.056)

  PMID:32661681 · one of two readings recorded this

• systolic blood pressure, seated, twice by OMRON HEM-907 automatic sphygmomanometer, over 12 weeks of daily 500 mL drink

  decreases, SBP decreased after EOJ versus control drink at all weeks except week 8 (borderline)

  Not recorded as a finding: the intervention held more than the compound

  After consumption of EOJ, SBP decreased in all evaluated weeks compared to CD, the decreases reaching significance (P < 0.05) at all weeks, with the only exception of week 8 in which a borderline significance (P = 0.078) was observed.

  PMID:32661681 · one of two readings recorded this

• Systolic blood pressure, trend with hesperidin content

  decreases, p = 0.05

  SBP decreased in a dose-dependent manner with the hesperidin content of the beverage administered (P < 0.05 for linear trend)

  PMID:32661681 · one of two readings recorded this

• Absolute initial power, Wingate test

  increases, p = 0.001

  there were increases in absolute (4.9% = 35.5 W; p = 0.001) and relative (4.3% = 0.44 W·kg−1; p = 0.004) initial power

  PMID:33371483 · one of two readings recorded this

• Absolute peak power, Wingate test

  increases, p = 0.001

  there was an increase in absolute (6.1% = 49.8 W; p < 0.001) and relative (5.6% = 0.64 W·kg−1; p = 0.001) peak power

  PMID:33371483 · one of two readings recorded this

• Absolute peak power, Wingate test

  increases, p = 0.016

  Placebo group showed an increase in absolute (6.1% = 47.2 W; p = 0.016) and relative peak power (5.6% = 0.64 W·kg−1; p = 0.014)

  PMID:33371483 · one of two readings recorded this

• Carbohydrate oxidation at VT1, change between groups

  no effect, p = 0.314

  No changes were found between groups in CHO (p = 0.314; ηp2 = 0.028; ES = 0.57) and FAT (p = 0.205; ηp2 = 0.044; ES = 0.53)

  PMID:33371483 · one of two readings recorded this

• Carbohydrate oxidation at VT1, pre-post

  increases, p = 0.02

  At VT1, there was a pre-post increase in carbohydrate oxidation (CHO) (p = 0.020) and a decrease pre-post in fat oxidation (p = 0.003) in Placebo group

  PMID:33371483 · one of two readings recorded this

• Correlation of urinary hesperidin metabolites with difference in estimated FTP

  increases, p = 0.001

  there was a positive correlation between the levels of excreted hesperidin metabolites in urine and the difference in maximum power (r = 0.701; p < 0.001) and estimated FTP (r = 0.725; p < 0.001) in the supplemented group

  PMID:33371483 · one of two readings recorded this

• Correlation of urinary hesperidin metabolites with difference in maximum power

  increases, p = 0.001

  there was a positive correlation between the levels of excreted hesperidin metabolites in urine and the difference in maximum power (r = 0.701; p < 0.001) and estimated FTP (r = 0.725; p < 0.001) in the supplemented group

  PMID:33371483 · one of two readings recorded this

• Cycling efficiency at FatMax, pre-post

  decreases, p = 0.01

  At FatMax, there was a pre-post decrease in fat oxidation (FAT) (p = 0.007) and efficiency (p = 0.010) in the Placebo group

  PMID:33371483 · one of two readings recorded this

• Estimated functional threshold power, change between groups

  increases, p = 0.042

  Between-group comparisons revealed an effect with the increase in estimated FTP (3.2% = 8.9 W; p = 0.042; ηp2 = 0.107; ES = 0.68)

  PMID:33371483 · one of two readings recorded this

• estimated functional threshold power (FTP = Pmax x 0.865 - 56.484) and maximum power achieved in an incremental step-plus-ramp cycle ergometer test, 8 weeks of 500 mg/day 2S-hesperidin (Cardiose) versus microcellulose placebo

  increases, estimated FTP +3.2% (8.9 W) and maximum power +2.7% (10.3 W) in the 2S-hesperidin group versus placebo, p = 0.042

  Not recorded as a finding: this platform holds no node for the endpoint

  Between-group comparisons revealed an effect with the increase in estimated FTP (3.2% = 8.9 W; p = 0.042; ηp2 = 0.107; ES = 0.68) and maximum power (2.7% = 10.3 W; p = 0.042; ηp2 = 0.107; ES = 0.68) in 2S-hesperidin group versus placebo.

  PMID:33371483 · one of two readings recorded this

• Estimated functional threshold power, pre-post change

  increases, p = 0.049

  there were pre-post increases in maximum power (1.9% = 7.4 W; p = 0.049) and estimated FTP (2.3% = 6.4 W; p = 0.049) in 2S-hesperidin group

  PMID:33371483 · one of two readings recorded this

• Estimated functional threshold power, pre-post change

  no effect, p = 0.387

  there were no changes in estimated FTP (−0.9 % = −2.51 W; p = 0.387) and maximum power (−0.8% = −2.9 W; p = 0.388) after the intervention in the placebo group

  PMID:33371483 · one of two readings recorded this

• Fat oxidation and efficiency at FatMax, pre-post

  no effect

  whereas the 2S-hesperidin supplemented group showed no changes in these parameters (Table 3)

  PMID:33371483 · one of two readings recorded this

• Fat oxidation at FatMax, change between groups

  no effect, p = 0.125

  No differences were found for between-group comparisons in FAT (p = 0.125; ηp2 = 0.084; ES = 0.59)

  PMID:33371483 · one of two readings recorded this

• Fat oxidation at FatMax, pre-post

  decreases, p = 0.007

  At FatMax, there was a pre-post decrease in fat oxidation (FAT) (p = 0.007) and efficiency (p = 0.010) in the Placebo group

  PMID:33371483 · one of two readings recorded this

• Fat oxidation at VT1, change between groups

  no effect, p = 0.205

  No changes were found between groups in CHO (p = 0.314; ηp2 = 0.028; ES = 0.57) and FAT (p = 0.205; ηp2 = 0.044; ES = 0.53)

  PMID:33371483 · one of two readings recorded this

• Fat oxidation at VT1, pre-post

  decreases, p = 0.003

  At VT1, there was a pre-post increase in carbohydrate oxidation (CHO) (p = 0.020) and a decrease pre-post in fat oxidation (p = 0.003) in Placebo group

  PMID:33371483 · one of two readings recorded this

• maximum power achieved in the incremental cycle-ergometer test to exhaustion and estimated functional threshold power (FTP = Pmax x 0.865 - 56.484); also VT1 and VT2 power, step-test VO2 and substrate oxidation, Wingate peak and initial power

  increases, estimated FTP 3.2% = 8.9 W and maximum power 2.7% = 10.3 W higher in the 2S-hesperidin group versus placebo, ES = 0.68, p = 0.042

  Not recorded as a finding: this platform holds no node for the endpoint

  Between-group comparisons revealed an effect with the increase in estimated FTP (3.2% = 8.9 W; p = 0.042; ηp2 = 0.107; ES = 0.68) and maximum power (2.7% = 10.3 W; p = 0.042; ηp2 = 0.107; ES = 0.68) in 2S-hesperidin group versus placebo.

  PMID:33371483 · one of two readings recorded this

• Maximum power, change between groups

  increases, p = 0.042

  and maximum power (2.7% = 10.3 W; p = 0.042; ηp2 = 0.107; ES = 0.68) in 2S-hesperidin group versus placebo

  PMID:33371483 · one of two readings recorded this

• Maximum power, pre-post change

  increases, p = 0.049

  there were pre-post increases in maximum power (1.9% = 7.4 W; p = 0.049) and estimated FTP (2.3% = 6.4 W; p = 0.049) in 2S-hesperidin group

  PMID:33371483 · one of two readings recorded this

• Maximum power, pre-post change

  no effect, p = 0.388

  there were no changes in estimated FTP (−0.9 % = −2.51 W; p = 0.387) and maximum power (−0.8% = −2.9 W; p = 0.388) after the intervention in the placebo group

  PMID:33371483 · one of two readings recorded this

• Power at maximum speed, Wingate test

  unclear, p = 0.051

  there was a trend towards an increase in power at maximum speed (4.4% = 34.0 W; p = 0.051)

  PMID:33371483 · one of two readings recorded this

• Power at VT1, change between groups

  no effect, p = 0.423

  without differences in VT1 power changes between groups (p = 0.423; ηp2 = 0.017; ES = 0.35)

  PMID:33371483 · one of two readings recorded this

• Power at VT1, pre-post change

  no effect, p = 0.437

  neither in 2S-hesperidin group (−3.7% = −6.0 W; p = 0.437)

  PMID:33371483 · one of two readings recorded this

• Power at VT1, pre-post change

  no effect, p = 0.453

  nor in Placebo group (3.4% = 5.3 W; p = 0.453)

  PMID:33371483 · one of two readings recorded this

• Power at VT2, change between groups

  no effect, p = 0.299

  Comparison between groups showed no effect (p = 0.299; ηp2 = 0.029; ES = 0.38)

  PMID:33371483 · one of two readings recorded this

• Power at VT2, pre-post change

  no effect, p = 0.642

  no changes were observed in 2S-hesperidin group (1.0% = 2.9 W; p = 0.642)

  PMID:33371483 · one of two readings recorded this

• Power at VT2, pre-post change

  no effect, p = 0.264

  there was no differences pre-post in power output in Placebo (−3.1% = −8.9 W; p = 0.264)

  PMID:33371483 · one of two readings recorded this

• Relative initial power, Wingate test

  increases, p = 0.004

  there were increases in absolute (4.9% = 35.5 W; p = 0.001) and relative (4.3% = 0.44 W·kg−1; p = 0.004) initial power

  PMID:33371483 · one of two readings recorded this

• Relative peak power, Wingate test

  increases, p = 0.001

  there was an increase in absolute (6.1% = 49.8 W; p < 0.001) and relative (5.6% = 0.64 W·kg−1; p = 0.001) peak power

  PMID:33371483 · one of two readings recorded this

• Relative peak power, Wingate test

  increases, p = 0.014

  Placebo group showed an increase in absolute (6.1% = 47.2 W; p = 0.016) and relative peak power (5.6% = 0.64 W·kg−1; p = 0.014)

  PMID:33371483 · one of two readings recorded this

• Time at maximum speed, Wingate test, change between groups

  unclear, p = 0.059

  Between-group comparison only reported a trend to decrease in time at maximum speed (−12.5% = −878.4 ms; p = 0.059) in Placebo compared with 2S-hesperidin

  PMID:33371483 · one of two readings recorded this

• Time at maximum speed, Wingate test

  decreases, p = 0.001

  a decrease in time at maximum speed (−13.2% = −929.2 ms; p = 0.001)

  PMID:33371483 · one of two readings recorded this

• Time at peak power, Wingate test

  unclear, p = 0.052

  a descending trend in time at peak power (−18.1% = −641.2 ms; p = 0.052) after the supplementation with 2S-hesperidin

  PMID:33371483 · one of two readings recorded this

• VO2 at VT2, pre-post change

  decreases, p = 0.002

  there was a decrease in VO2 (L/min) (−8.3%; p = 0.002) and VO2R (ml/kg/min) (−8.9%; p = 0.002) at VT2 in Placebo group

  PMID:33371483 · one of two readings recorded this

• VO2R at VT2, change between groups

  no effect, p = 0.074

  Between-group comparison showed a trend towards a decrease (p = 0.074; ηp2 = 0.084; ES = 0.67) in VO2R (mL/kg/min) for placebo versus 2S-hesperidin group

  PMID:33371483 · one of two readings recorded this

• VO2R at VT2, pre-post change

  decreases, p = 0.002

  there was a decrease in VO2 (L/min) (−8.3%; p = 0.002) and VO2R (ml/kg/min) (−8.9%; p = 0.002) at VT2 in Placebo group

  PMID:33371483 · one of two readings recorded this

The whole record — 398 rows